Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.52 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | NOD2 | Q9HC29 | 3/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2162546 | 0.78 | MEN1 (0.61) | MAPTSMN1; SMN2TDP1KDM4EALDH1A1 | |
| SCHEMBL25811430 | 0.77 | PTGDR2 (0.51) | PTGDR2PTGDR | |
| SCHEMBL10853593 | 0.76 | HCRTR1 (0.50) | MAPTRAB9ASMN1; SMN2TDP1MAPK1 | |
| SCHEMBL2162591 | 0.76 | TDP1 (0.76) | MAPTTDP1KDM4EL3MBTL1LMNA | |
| SCHEMBL25811417 | 0.76 | MAPT (0.57) | MAPTSMN1; SMN2MAPK1KDM4EALDH1A1 | |
| SCHEMBL24015624 | 0.75 | HTR6 (0.52) | PTGDR2PTGDRLMNA | |
| SCHEMBL25811424 | 0.75 | HTR6 (0.50) | PTGDR2PTGDRNOD1 | |
| SCHEMBL2161385 | 0.74 | TDP1 (0.61) | MAPTSMN1; SMN2TDP1KDM4EL3MBTL1 | |
| SCHEMBL2005697 | 0.74 | NOD2 (0.53) | PTGDR2PTGDRNOD2NOD1KDM4E | |
| SCHEMBL11622012 | 0.74 | NOD1 (0.55) | MAPTRAB9ASMN1; SMN2NPC1NOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | GALYAN BIO INC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-4110463-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Galyan Bio, Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218573-A1 | INDOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | HTT, HYPK, PARK7 | PTGDR2 4166/4885PTGDR 3816/4885MAPT 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.